Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of Panblok-H5 with Advax Adjuvant
NCT02335164Phase 1Completed
- Sponsor
- Vaxine
- Start
- Jul 2015
- Primary completion
- Dec 2017
- Modality
- Vaccines & Immunotherapeutics, Liposomes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Panblok-H5 and ADVAX in Avian influenza H5N1 (H5N1) (9 arms), sponsored by Vaxine. Primary endpoint: Incidence of adverse events at 12 months. Started Jul 2015; status: completed.
02
Drugs
Panblok-H5ADVAX
03
Conditions
Avian influenza H5N1 (H5N1)
Beyond the preview
Go deeper on NCT02335164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02335164.